Phase 2 × Graft vs Host Disease × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT01044745 2023-09-06

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

University of Nebraska

Phase 2 Terminated
20 enrolled 8 charts
NCT02500550 2021-05-18

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Kiadis Pharma

Phase 2 Completed
15 enrolled 15 charts
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT00096161 2020-01-31

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 13 charts
NCT00003270 2019-12-13

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT01240525 2019-02-12

ProT4

University College, London

Phase 2 Unknown
114 enrolled
NCT00001873 2018-09-26

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts